Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Migraine Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Acute Migraine Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and quantity-limit review for selected acute migraine therapies for Boeing commercial members, including initial and renewal criteria, prerequisite therapy requirements, quantity-limit exceptions, and 12-month approval durations.

    Policy Summary
    PayerPrime Therapeutics
    PolicyAcute Migraine Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the applicable indication, safety evidence, and prerequisite therapy documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Targeted brand agents
    12 monthsApproval duration
    >4/monthMigraine threshold
    1 agentTriptan prerequisite

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Rule out
    Medication-overuse headache

    Coverage Criteria

    Initial evaluation — general criteria

    Covered when ALL of the following initial-evaluation requirements are met.

    General initial requirements

    • Qualifying indication

      • Acute migraine indication: The requested agent is being used for the acute treatment of migraine.
      • Other FDA-labeled indication: The requested agent is being used for another FDA-labeled indication and route of administration.
      • Compendia-supported indication: The requested agent is being used for an indication supported by AHFS or DrugDex evidence level 1, 2a, or 2b.
    • Age support when FDA labeling applies

      • The patient's age is within FDA labeling for the requested indication and agent.
      • There is support for use of the requested agent for the patient's age and requested indication.
    • Safety: The patient does not have an FDA-labeled contraindication to the requested agent.

    Initial evaluation — prerequisite therapy

    For acute migraine treatment, the applicable agent-specific prerequisite pathway must also be met.

    Applicable prerequisite pathway

    • Triptan prerequisite: The patient tried and had an inadequate response to one triptan or triptan combination agent; had intolerance or hypersensitivity to one triptan or triptan combination agent; or has an FDA-labeled contraindication to all triptan and triptan combination agents.
    • Reyvow pathway

      • Triptan prerequisite: The patient tried and had an inadequate response to one triptan or triptan combination agent; had intolerance or hypersensitivity to one triptan or triptan combination agent; or has an FDA-labeled contraindication to all triptan and triptan combination agents.
      • The patient will not use Reyvow in combination with another acute migraine therapy, including a 5HT-1F agent, acute-use CGRP agent, ergotamine, or triptan.

    Renewal therapy

    Covered for renewal when ALL of the following are met.

    Renewal requirements

    • The patient was previously approved for the requested agent through the plan's prior authorization process.

      Patients without previous plan approval require initial evaluation.

    • The patient has had clinical benefit with the requested agent.
    • The patient does not have an FDA-labeled contraindication to the requested agent.
    • Reyvow use restriction

      • The requested agent is not Reyvow.
      • The requested agent is Reyvow; the patient will not use it in combination with another acute migraine therapy, including a 5HT-1F agent, acute-use CGRP agent, ergotamine, or triptan; and medication-overuse headache has been ruled out.

    Quantity-limit exceptions

    A quantity-limit exception is covered through one of the following pathways.

    Quantity-limit pathways

    • Within program limit: The requested quantity or dose does not exceed the program quantity limit.
    • Above limit but within FDA maximum

      • The requested quantity or dose exceeds the program quantity limit.
      • The requested quantity or dose does not exceed the maximum FDA-labeled dose for the requested indication.
      • The requested quantity or dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
    • Above FDA maximum dose

    Coverage is excluded when the requested agent is used in a patient with an FDA-labeled contraindication to that agent.

    Reyvow is not approved when it will be used in combination with another acute migraine therapy, including a 5HT-1F agent, acute-use CGRP agent, ergotamine, or triptan. Medication-overuse headache must also be ruled out when required by the applicable pathway.

    Requests are not medically necessary when the requested agent lacks an eligible FDA-labeled indication or a compendia-supported indication for the requested agent and route. Compendia support must be based on AHFS or DrugDex evidence level 1, 2a, or 2b. Coverage may also be denied when the patient's age is outside FDA labeling without supporting age-specific evidence, when the patient lacks the applicable prerequisite therapy, or when required evidence of an alternative indication, age-specific use, or safety is not provided.

    A quantity-limit exception may be denied when the requested dose exceeds the program limit and does not meet the applicable exception pathway. For a request that remains within the maximum FDA-labeled dose, the dose must not be achievable with a lower quantity of a higher strength that remains within the program limit. For a request exceeding the FDA-labeled maximum, the patient must have more than 4 migraine headaches per month, meet an applicable prophylaxis condition, have medication-overuse headache ruled out, and have support for higher-dose therapy for the requested indication.

    Coding and Thresholds

    Migraine frequency for higher quantity exception
    Threshold>4 migraine headaches per month
    Applies whenThe requested quantity exceeds both the program quantity limit and the maximum FDA-labeled dose for the requested indication.
    Additional requirementThe request must also meet an applicable prophylaxis condition, rule out medication-overuse headache, and include support for higher-dose therapy.

    Provider Actions

    Prior Authorization

    Initial Prior Authorization

    Submit an initial prior authorization request for the target agent. Covered target agents include Elyxyb (celecoxib), Migranal (dihydroergotamine mesylate), Reyvow (lasmiditan), Brekiya (dihydroergotamine mesylate), and Trudhesa (dihydroergotamine mesylate HFA).

    • Document the applicable indication, prerequisite therapy, age, safety, and treatment-history requirements.
    • Initial approval is for 12 months; if a quantity limit applies, submit the request under the Quantity Limit Criteria.
    Prior Authorization

    Renewal Prior Authorization

    For renewal, document that the patient was previously approved for the requested agent through the plan's prior authorization process and has experienced clinical benefit. Renewal approval is for 12 months when all renewal requirements are met.

    • Patients without prior plan approval require initial evaluation review.
    • Document that medication-overuse headache has been ruled out and that the patient has no FDA-labeled contraindication to the requested agent.

    Policy Background

    This policy addresses prescription therapies used for the acute treatment of migraine, while permitting review of other FDA-labeled indications or indications supported by AHFS or DrugDex at evidence level 1, 2a, or 2b. Coverage review includes prior therapy requirements, safety and contraindication screening, medication-overuse headache assessment, and quantity-limit controls. Quantity-limit exceptions apply additional dose and clinical requirements, including migraine frequency, prophylaxis status or limitations, and support for higher-dose treatment.

    Definitions

    Compendia Allowed
    AHFSEvidence level 1, 2a, or 2b.
    DrugDexEvidence level 1, 2a, or 2b.
    Permitted evidenceCompendia support is limited to AHFS or DrugDex evidence level 1, 2a, or 2b.
    Maximum FDA-labeled dose
    DefinitionThe maximum dose labeled by the FDA for the requested indication.
    Applies toThe requested indication.
    Quantity-limit reviewA quantity-limit exception request may not exceed this dose unless the enhanced clinical exception criteria are met.

    Initial Authorization Criteria

    Initial authorization

    Initial approval requires ALL general indication and safety criteria plus the applicable agent-specific pathway.

    Initial authorization requirements

    • Qualifying indication

      • The requested agent is being used for the acute treatment of migraine.
      • The requested agent is being used for another FDA-labeled indication and route of administration.
      • The requested agent is being used for an indication supported by AHFS or DrugDex evidence level 1, 2a, or 2b.
    • Age support when FDA labeling applies

    Renewal Criteria

    Renewal criteria

    Renewal is covered when ALL of the following are met.

    Continuation criteria

    • Prior approval for the requested agent through the plan's prior authorization process is documented.
    • The patient has had clinical benefit with the requested agent.
    • The patient does not have an FDA-labeled contraindication to the requested agent.
    • Reyvow use restriction

      • The requested agent is not Reyvow.

    Step Therapy Requirements

    StepApplies toRequired prerequisiteExceptions / alternatives
    1Elyxyb, Migranal, Reyvow, Brekiya, and TrudhesaTry one triptan or triptan combination agent and demonstrate an inadequate response.The prerequisite may be waived when the patient has intolerance or hypersensitivity to one triptan or triptan combination agent, or an FDA-labeled contraindication to all triptan and triptan combination agents.
    StepApplies toRequired prerequisiteExceptions / alternatives
    2Brekiya or TrudhesaTry one generic dihydroergotamine injection agent.The prerequisite may be waived when the patient has an inadequate response to, intolerance or hypersensitivity to, or an FDA-labeled contraindication to all generic dihydroergotamine injection agents, provided the intolerance or contraindication is not expected with the requested agent. It may also be waived when there is support for using the requested agent over generic injectable dihydroergotamine.

    Quantity Limits

    Quantity limits
    BrekiyaA program quantity limit applies; the numeric quantity, day supply, and duration are not stated.
    ElyxybA program quantity limit applies; the numeric quantity, day supply, and duration are not stated.
    MigranalA program quantity limit applies; the numeric quantity, day supply, and duration are not stated.
    ReyvowA program quantity limit applies; the numeric quantity, day supply, and duration are not stated.
    TrudhesaA program quantity limit applies; the numeric quantity, day supply, and duration are not stated.
    Policy Summary
    PayerPrime Therapeutics
    PolicyAcute Migraine Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the applicable indication, safety evidence, and prerequisite therapy documentation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and ThresholdsProvider ActionsPolicy BackgroundDefinitionsInitial Authorization CriteriaRenewal CriteriaStep Therapy RequirementsQuantity Limits
    Medication-overuse headache has been ruled out.
  1. Brekiya or Trudhesa pathway

    • Triptan prerequisite: The patient tried and had an inadequate response to one triptan or triptan combination agent; had intolerance or hypersensitivity to one triptan or triptan combination agent; or has an FDA-labeled contraindication to all triptan and triptan combination agents.
    • Generic dihydroergotamine prerequisite

      • The patient tried and had an inadequate response to one generic dihydroergotamine injection agent.
      • The patient had intolerance or hypersensitivity to one generic dihydroergotamine injection agent that is not expected to occur with the requested agent.
      • The patient has an FDA-labeled contraindication to all generic dihydroergotamine injection agents that is not expected to occur with the requested agent.
      • There is support for use of Brekiya or Trudhesa over generic injectable dihydroergotamine.
    • Medication-overuse headache has been ruled out.
    • The requested quantity or dose exceeds the program quantity limit.
    • The requested quantity or dose exceeds the maximum FDA-labeled dose for the requested indication.
    • The patient has greater than 4 migraine headaches per month.>4 migraine headaches per month
    • Prophylaxis condition

      • The patient is currently being treated with a migraine prophylactic medication.
      • The patient has intolerance or hypersensitivity to migraine prophylactic medication.
      • The patient has an FDA-labeled contraindication to all migraine prophylactic medications.
      • There is support that the patient's migraines are manageable with acute therapy alone.
    • Medication-overuse headache has been ruled out.
    • There is support for therapy with a higher dose for the requested indication.
  2. For Reyvow, document that it will not be used with another acute migraine therapy.
  3. Billing Rule

    Quantity-Limit Review and Duration

    Review the requested quantity against the program limit and document the applicable exception pathway when the request exceeds that limit. Quantity-limit approvals are for 12 months.

    • Within-limit requests are approvable when the requested dose does not exceed the program quantity limit.
    • For an above-limit request that remains within the maximum FDA-labeled dose, document that the dose cannot be achieved with a lower quantity of a higher strength within the limit.
    • For a request above both the program limit and maximum FDA-labeled dose, document more than 4 migraine headaches per month, the required prophylaxis-related exception, that medication-overuse headache has been ruled out, and support for the higher dose.
    Step Therapy

    Triptan Prerequisite

    Document a qualifying trial of at least one triptan or triptan combination agent for the requested acute migraine therapy. The prerequisite may be met by inadequate response, intolerance or hypersensitivity, or an FDA-labeled contraindication to all triptan and triptan combination agents.

    • For an inadequate response, identify the triptan or triptan combination agent tried and the inadequate outcome.
    • For intolerance or hypersensitivity, identify the agent and reaction.
    • For a contraindication pathway, document FDA-labeled contraindication to all triptan and triptan combination agents.

    Unsupported block type: step_therapy

    Documentation Required

    Acute Migraine Treatment History

    For acute migraine treatment, document the requested agent's intended use and the patient's prior acute migraine treatment history. The record must support a qualifying triptan or triptan-combination trial unless an alternative labeled or compendia-supported indication applies.

    • Identify the requested agent and route of administration.
    • Document the prior acute migraine therapy, response, intolerance or hypersensitivity, or applicable contraindication.
    • Document that medication-overuse headache has been ruled out when the request is for acute migraine treatment.
    Documentation Required

    Indication and Safety Support

    Provide clinical documentation supporting the requested indication and route of administration, the patient's age when an FDA-labeled indication is used, and absence of FDA-labeled contraindications.

    • The request may be supported by another FDA-labeled indication or an indication supported by AHFS or DrugDex level 1, 2a, or 2b evidence.
    • For an FDA-labeled indication, document that the patient's age is within labeling or provide support for use at the patient's age.
    • Document that the patient does not have an FDA-labeled contraindication to the requested agent.
    Documentation Required

    Renewal Documentation

    For renewal, submit evidence of prior plan approval and clinical benefit with the requested agent. The renewal record must also address acute migraine safety requirements when applicable.

    • Document prior approval through the plan's prior authorization process.
    • Document clinical benefit with the requested agent.
    • For Reyvow, document that it will not be used with another acute migraine therapy; document that medication-overuse headache has been ruled out and that no FDA-labeled contraindication is present.

    Unsupported block type: documentation

    Denial Risk

    No Qualifying Triptan History

    Requests are at risk for denial when the patient has no qualifying triptan or triptan-combination history and no adequate documentation of intolerance, hypersensitivity, or an FDA-labeled contraindication to all such agents.

    • An undocumented or nonqualifying prior trial does not satisfy the prerequisite.
    • For acute migraine treatment, medication-overuse headache must also be ruled out.
    • Brekiya and Trudhesa additionally require the generic dihydroergotamine prerequisite or documented support for using the requested agent over generic injection.
    Denial Risk

    Unsupported Indication, Age, or Contraindication

    Denial may result when the requested use is not an FDA-labeled or compendia-supported indication, the patient's age is unsupported for the labeled indication, or an FDA-labeled contraindication to the requested agent is present.

    • Compendia support must be from AHFS or DrugDex with level 1, 2a, or 2b evidence.
    • For an FDA-labeled indication, the patient's age must be within labeling or supported for the requested indication.
    • The requested agent must not have an FDA-labeled contraindication for the patient.
    Denial Risk

    Prohibited Acute Migraine Combination

    Reyvow may be denied when the patient will use it in combination with another acute migraine therapy. The prohibited combinations include another 5HT-1F agent, acute-use CGRP agent, ergotamine, or triptan.

    • Apply this restriction during initial and renewal review.
    • Document that the requested Reyvow therapy will not be combined with another acute migraine therapy.
    Denial Risk

    Generic Dihydroergotamine Prerequisite Not Met

    Brekiya or Trudhesa may be denied when the generic dihydroergotamine injection prerequisite is not met or the required exception rationale is not documented.

    • No qualifying inadequate response to one generic dihydroergotamine injection agent is documented.
    • No qualifying intolerance or hypersensitivity, or FDA-labeled contraindication to all generic dihydroergotamine injection agents, is documented.
    • No support for using the requested agent over generic dihydroergotamine injection agents is provided.
    Denial Risk

    Renewal History or Benefit Missing

    Renewal may be denied when the patient lacks prior plan approval, clinical benefit, or required safety and combination-use documentation.

    • Patients not previously approved through the plan's prior authorization process require initial evaluation review.
    • No clinical benefit with the requested agent is documented.
    • For Reyvow, use with another acute migraine therapy, failure to rule out medication-overuse headache, or an FDA-labeled contraindication is not resolved.
    Denial Risk

    Quantity-Limit Exception Criteria Not Met

    A quantity-limit exception may be denied when the requested dose or supporting clinical circumstances do not meet the program criteria.

    • The requested quantity exceeds the program limit without remaining within the maximum FDA-labeled dose or without showing that a lower quantity of a higher strength cannot achieve the dose.
    • For requests above the maximum FDA-labeled dose, more than 4 migraine headaches per month or a qualifying prophylaxis-related exception is not documented.
    • Medication-overuse headache has not been ruled out or support for the higher dose is absent.
    Quantity-limit exception
    DefinitionA dose request above the program quantity limit that meets the policy's additional clinical and dosing conditions.
    Within FDA maximumThe requested quantity exceeds the program limit but does not exceed the maximum FDA-labeled dose and cannot be achieved with a lower quantity of a higher strength within the program limit.
    Above FDA maximumThe requested quantity exceeds the program limit and maximum FDA-labeled dose and requires greater than 4 migraine headaches per month, an applicable prophylaxis condition, no medication-overuse headache, and support for higher-dose therapy.
    The patient's age is within FDA labeling for the requested indication and agent.
  4. There is support for use of the requested agent for the patient's age and requested indication.
  5. The patient does not have an FDA-labeled contraindication to the requested agent.
  6. Agent-specific pathway

    • The patient tried and had an inadequate response to one triptan or triptan combination agent; had intolerance or hypersensitivity to one; or has an FDA-labeled contraindication to all triptan and triptan combination agents.
    • Reyvow

      • The patient meets the applicable triptan prerequisite.
      • The patient will not use Reyvow with another acute migraine therapy, including a 5HT-1F agent, acute-use CGRP agent, ergotamine, or triptan.
      • Medication-overuse headache has been ruled out.
    • Brekiya or Trudhesa

      • The patient meets the applicable triptan prerequisite.
      • The patient meets the generic dihydroergotamine injection prerequisite through inadequate response, intolerance or hypersensitivity not expected with the requested agent, an FDA-labeled contraindication not expected with the requested agent, or support for use of the requested agent over generic injectable dihydroergotamine.
      • Medication-overuse headache has been ruled out.
  7. The requested agent is Reyvow and will not be used with another acute migraine therapy, including a 5HT-1F agent, acute-use CGRP agent, ergotamine, or triptan; medication-overuse headache has been ruled out.